Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010
During the fourth quarter of 2010, 86 biopharmaceutical financings totalled $5.73 billion altogether, a whopping 239% increase over the previous three-month period in which 71 deals garnered $1.69 billion. M&A dollar volume also increased - 20 acquisitions brought in a combined $9.4 billion, a large chunk of which was Pfizer's $3.56 billion buy of King. And alliances between universities and biopharma companies, particularly Big Pharma and start-ups, were abundant.
You may also be interested in...
Reckitt Benckiser will enhance its personal-care offering and position itself for growth in the dynamic Indian market with its acquisition of Paras Pharmaceuticals Ltd. for roughly $725 million.
In a rare early-stage R&D collaboration, two Big Pharmas will evaluate novel combinations of signaling-pathway anticancers.
FDA Commissioner Hamburg and CDER Director Woodcock outline the requirements for developing drugs in combination during the Faster Cures Partnering for Cures meeting in New York.